CALA Stock Overview
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.
Notes are coming soon
Calithera Biosciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.38|
|52 Week High||US$14.87|
|52 Week Low||US$0.36|
|1 Month Change||-87.86%|
|3 Month Change||-85.87%|
|1 Year Change||-95.45%|
|3 Year Change||-99.68%|
|5 Year Change||-99.74%|
|Change since IPO||-99.80%|
Recent News & Updates
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?Aug 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyDec 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyAug 27
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?May 02
What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?Mar 10
Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value EstimateJan 17
Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In GrowthDec 13
|CALA||US Biotechs||US Market|
Return vs Industry: CALA underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: CALA underperformed the US Market which returned -9.7% over the past year.
|CALA Average Weekly Movement||29.9%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CALA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 30% a week.
Volatility Over Time: CALA's weekly volatility has increased from 21% to 30% over the past year.
About the Company
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1.
Calithera Biosciences, Inc. Fundamentals Summary
|CALA fundamental statistics|
Is CALA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CALA income statement (TTM)|
|Cost of Revenue||US$49.51m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-17.18|
|Net Profit Margin||0.00%|
How did CALA perform over the long term?See historical performance and comparison